Chemotherapy for Multiple Myeloma
Currently, there is no cure for myeloma, so treatment is designed to prolong life by reducing the effects of myeloma on body functions and reducing discomfort from the disease. Chemotherapy is usually given after symptoms or complications develop because there has been no evidence that early treatment alters the course of the disease. Chemotherapy drugs are usually used in combination and given in cycles. The drugs can be given intravenously (IV) or by mouth. The drugs given by IV may be administered at the doctor’s office or in the hospital. Oral drugs may be taken at home.
Chemotherapy is given until the abnormal antibody-like protein produced by myeloma cells decreases and reaches a plateau. A complete remission—a total loss of the abnormal protein or total destruction, at least for a time, of the cells that make up myeloma—is rare.
The type of chemotherapy recommended often depends on the amount of tumor present in your body and your kidney function.
Chemotherapy Drugs Used for Multiple Myeloma
- Cyclophosphamide (Cytoxan)
- Dexamethasone (Decadron), may be used alone
- Doxorubicin (Adriamycin0
- Melphalan (Alkeran)
- Vincristine (Oncovin)
- Melphalan (Alkeran)
Taken by mouth daily for four days every four to six weeks, typically for a year.
- Vincristine (Oncovin), given by IV
- Doxorubicin (Adriamycin), given by IV, continuous infusion
- Dexamethasone (Decadron), taken by mouth
This combination starts acting faster than MP. It is given on four days starting on days 1, 9, and 17 of each month.
Fifty to sixty percent of patients receiving either regimen reduce the amount of abnormal protein in their blood by half, but fewer than one in twenty has a complete remission. Typically, multiple myeloma recurs within one to two years of ending chemotherapy. At this point, the doctor will usually recommend trying the other chemotherapy regimen; typically MP is given first, and VAD is given when the disease comes back.
Side Effects and Possible Complications
Melphalan may increase your risk of developing
National Cancer Institute website. Available at: http://www.cancer.gov/ .
Nissen D. Mosby's Drug Consult. St. Louis, MO:Mosby, Inc; 2002.
Rakel R. Bope E, ed. Conn's Current Therapy 2002. 54th ed. St. Louis, MO: WB Saunders Company; 2002: 439-443.
Last reviewed May 2007 by
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.